Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-03-15
2005-03-15
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S051000, C514S851000, C514S378000, C514S008100, C514S912000, C536S023500, C536S026230, C536S025600, C424S046000, C424S045000, C424S489000, C546S229000
Reexamination Certificate
active
06867199
ABSTRACT:
The present invention relates to certain novel dinucleoside polyphosphates of general Formulae I, II and III, and formulations thereof which are selective ligands of the P2Y purinergic receptors. Applicants have discovered that dinucleoside polyphosphates of general Formulae I, II and III are effective in clearing retained mucous secretions, balancing tissue hydration and fluid secretion, and/or inhibiting or preventing early stages of platelet activation, platelet degranulation, and platelet aggregation.
REFERENCES:
patent: 4855304 (1989-08-01), Devash
patent: 5292498 (1994-03-01), Boucher
patent: 5635160 (1997-06-01), Stutts et al.
patent: 5681823 (1997-10-01), Kim et al.
patent: 5721219 (1998-02-01), Ingall et al.
patent: 5837861 (1998-11-01), Pendergast et al.
patent: 5900407 (1999-05-01), Yerxa et al.
patent: 6040297 (2000-03-01), De Flora
patent: 6159952 (2000-12-01), Shaffer et al.
patent: 6258374 (2001-07-01), Friess et al.
patent: 6331529 (2001-12-01), Yerxa et al.
patent: 6458946 (2002-10-01), Maeda et al.
patent: 6555675 (2003-04-01), Rideout et al.
patent: 6596725 (2003-07-01), Peterson et al.
patent: 20020052336 (2002-05-01), Yerxa et al.
patent: 20020156269 (2002-10-01), Maeda et al.
patent: 1 191 032 (2002-03-01), None
patent: 1 043 329 (2002-08-01), None
patent: 689202 (1993-10-01), None
patent: WO 9602554 (1996-02-01), None
patent: WO 9640059 (1996-12-01), None
patent: WO 9815563 (1998-04-01), None
patent: WO 9834593 (1998-08-01), None
patent: WO 9834942 (1998-08-01), None
patent: WO 9855494 (1998-12-01), None
patent: WO 9905142 (1999-02-01), None
patent: WO 0030629 (2000-06-01), None
patent: WO 0187913 (2001-11-01), None
patent: W0 02096428 (2002-12-01), None
U.S. Appl. No. 09/570,231, Peterson, filed May 12, 2000.
Brown, et al.,Mol. Pharmocol. 40, 648-55 (1991).
Burnstock, et al., “P2 purinergic receptors: Modulation of cell function and therapeutic potential,”Journal of Pharmacology and Experimental Therapeutics 295(3) 862-869 (2000) XP002208652.
Drutz, et al.,Drug Dev. Res. 37(3), 185 (1996).
Ferris, et al., “Oligomerization reactions of deoxyribonucleotides on montmorillonite clay: the effect of mononucleotide structure on phosphodiester bond formation,”Origins Life Evol. Biosphere, 19(6):609-619 (1989) XP001085277.
Gobran,Am. J. Physiol. 267, L625-L633 (1994).
Guranowski, et al.,Nucleosides and Nucleotides 14:731-734 (1995).
Lethem, et al.,Am. J. Respir. Cell Mol. Biol. 9, 315-22 (1993).
Maminishkis, et al., “Purinoceptor agonists increase fluid clearance out of subretinal space (SRS) blebs in vivo,”IOVS, 41(4):S136 (2000) XP001083820.
Mason, et al.,Br. J. Pharmacol. 103, 1649-56 (1991).
Peterson, et al., “Extracellular ATP activates calcium signaling, ion, and fluid transport in retinal pigment epithelium,”Journal of Neuroscience, 17:(7)2324-2337 (1997) XP001087693.
Scheffzek, et al., Crystal Structure of the Complex of UMP/CMP Kinase fromDictyostelium discoideum and the Bisubstrate inhibitor P1-(5′-Adenosyl) P5-(5′Uridyl) Pentaphosphate (UP5A) and Mg2+at 2.2A: Implications for Water-Mediated Specificity,Biochemistry 35:9716-9727 (1996).
Sillero, et al., (2′,3′-Dideoxynucleoside triphosphates (ddNTP) and di-2′,3′-dideoxynucleoside tetraphosphates (ddNp4ddN) behave differently to the corresponding NTP and NP4N counterparts as substrates of firefly luciferase, and dinucleoside tetraphosphatase and phosphodiesterases,Biochemica et Biophysica Acta 1334(2-3):191-199 (1997) XP002208651.
Theoclitou, et al., “Characterization of stress protein LysU. Enzyme synthesis of diadenosine 5′,5′-P1,P4-tetraphosphate (Ap4A) analogs by LysU,”J. Chem. Soc., Perkins Trans. 1(16):2009-2019 (1996) XP00108769.
Visscher, et al. “Selective Cleavage of pyrophosphate linkages,”Nucleic Acids Research 20(21):5749-5752 (1992).
Douglass, III James G.
Rideout Janet L.
Shaver Sammy Ray
Yerxa Benjamin R.
Howrey Simon Arnold & White , LLP
Inspire Pharmaceuticals Inc.
Khare Devesh
Kung Viola T.
Wilson James O.
LandOfFree
Dinucleoside polyphosphate compositions and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dinucleoside polyphosphate compositions and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dinucleoside polyphosphate compositions and their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3402938